Emmaus Life Sciences Reports 124% Revenue Growth and Net Income Turnaround in Latest Quarter

Emmaus Life Sciences, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company achieved net revenues of $6.3 million for the quarter, a 124% increase from $2.8 million in the same period last year. This growth was primarily driven by the recognition of $4.8 million in revenue from an upfront fee and royalties under a new licensing agreement with NeoImmuneTech, Inc. (NIT). Despite this revenue increase, the company recorded a net income of $1.3 million, a turnaround from a net loss of $1.1 million in the prior year, reflecting improved operational performance.

In terms of operational metrics, Emmaus reported a decrease in direct sales of its only product, Endari®, which was partially offset by the new revenue streams from the licensing agreement. The cost of goods sold rose to $0.3 million, reflecting a 129% increase due to higher sales volume, including the transfer of 3,000 cartons of Endari® to NIT. Selling expenses decreased by 27% to $0.5 million, attributed to the transfer of the U.S. sales force to NIT, while general and administrative expenses fell by 32% to $1.6 million, driven by reduced payroll and professional service costs.

The company’s balance sheet as of June 30, 2026, showed total assets of $16.4 million, down from $21.4 million at the end of 2025. Current liabilities decreased slightly to $66.1 million, while stockholders' deficit widened to $66.2 million from $63.6 million. The company’s cash and cash equivalents increased to $2.8 million, up from $2.1 million at the end of the previous fiscal year. However, Emmaus continues to face substantial liquidity challenges, with a working capital deficit of $60.1 million and ongoing concerns about its ability to meet future obligations without additional financing.

Strategically, the licensing agreement with NIT, effective May 15, 2026, marks a significant shift in Emmaus's business model, as it transitions to a royalty-based revenue structure. Under this agreement, NIT has exclusive rights to market and distribute Endari® in the U.S. and Canada, while Emmaus will supply the product at a cost-plus margin. The company has also indicated that it will need to explore additional financing options, including loans and equity financing, to sustain operations and meet its financial commitments.

Looking ahead, Emmaus remains cautious about its financial outlook. The company has acknowledged that its existing cash balance and anticipated cash flows are insufficient to fund its current obligations over the next 12 months. As such, it is actively seeking to restructure or refinance its existing debt and raise additional funds through various means. The management has expressed uncertainty regarding the company's ability to generate increased revenues or achieve sustainable profitability in the near future, emphasizing the need for strategic transactions to bolster its financial position.